These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 944786)

  • 1. Diester derivatives as apomorphine prodrugs.
    Borgman RJ; Baldessarini RJ; Walton KG
    J Med Chem; 1976 May; 19(5):717-9. PubMed ID: 944786
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prolonged apomorphine-like behavioural effects of apomorphine esters.
    Borgman RJ
    Neuropharmacology; 1976 Aug; 15(8):471-8. PubMed ID: 988501
    [No Abstract]   [Full Text] [Related]  

  • 3. Lipophilic prodrugs of apomorphine I: preparation, characterisation, and in vitro enzymatic hydrolysis in biorelevant media.
    Borkar N; Li B; Holm R; Håkansson AE; Müllertz A; Yang M; Mu H
    Eur J Pharm Biopharm; 2015 Jan; 89():216-23. PubMed ID: 25513957
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vivo evaluation of lipid-based formulations for oral delivery of apomorphine and its diester prodrugs.
    Borkar N; Holm R; Yang M; Müllertz A; Mu H
    Int J Pharm; 2016 Nov; 513(1-2):211-217. PubMed ID: 27615708
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hydrolysis of diester prodrugs of apomorphine.
    Baldessarini RJ; Kula NS; Walton KG; Borgman RJ
    Biochem Pharmacol; 1977 Oct; 26(19):1749-56. PubMed ID: 907714
    [No Abstract]   [Full Text] [Related]  

  • 6. Enhancement of transdermal apomorphine delivery with a diester prodrug strategy.
    Liu KS; Sung KC; Al-Suwayeh SA; Ku MC; Chu CC; Wang JJ; Fang JY
    Eur J Pharm Biopharm; 2011 Aug; 78(3):422-31. PubMed ID: 21315820
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Behavioral supersensitivity to apomorphine and amphetamine after chronic high dose haloperidol treatment.
    Smith RC; Davis JM
    Psychopharmacol Commun; 1975; 1(3):285-93. PubMed ID: 1241453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prolonged modulation of FGF-2 expression in astrocytic cultures induced by O,O'-diacetyl-apomorphine.
    He X; Wang D; Zhang X; Li A; Gu X; Ding F; Zhou J
    Biochem Biophys Res Commun; 2008 May; 369(3):824-9. PubMed ID: 18312850
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Snout contact fixation, climbing and gnawing during apomorphine stereotypy in rats from two substrains.
    Szechtman H; Ornstein K; Teitelbaum P; Golani I
    Eur J Pharmacol; 1982 Jun; 80(4):385-92. PubMed ID: 7201932
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Behavioral effects and cerebral pharmacokinetics of apomorphine in the rat: dependence upon the route of administration.
    Melzacka M; Wiszniowska G; Daniel W; Vetulani J
    Pol J Pharmacol Pharm; 1979; 31(4):309-17. PubMed ID: 574957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intermittency in mastication and apomorphine-induced gnawing.
    Gerstner GE
    Physiol Behav; 1998 Dec; 65(3):569-74. PubMed ID: 9877425
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apomorphine-induced locomotion and gnawing: evidence that the experimental design greatly influences gnawing while locomotion remains unchanged.
    Ljungberg T; Ungerstedt U
    Eur J Pharmacol; 1977 Nov; 46(2):147-51. PubMed ID: 563330
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of apomorphine-induced behaviors by derivatives of 2-amino-1, 2, 3, 4-tetrahydronaphthalene.
    Rusterholz DB; Long JP; Flynn JR; Glyn JR; Barfknecht CF; Lind RW; Johnson AK
    Arch Int Pharmacodyn Ther; 1978 Apr; 232(2):246-60. PubMed ID: 567044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. O-methylation of apomorphine and the metabolic prolongation of apomorphine-induced stereotyped behaviour.
    Missala K; Lal S; Sourkes TL
    Eur J Pharmacol; 1973 Apr; 22(1):54-8. PubMed ID: 4735946
    [No Abstract]   [Full Text] [Related]  

  • 15. Lesions of substantia nigra by kainic acid: effects on apomorphine-induced stereotyped behaviour.
    Morelli M; Porceddu ML; Di Chiara G
    Brain Res; 1980 Jun; 191(1):67-78. PubMed ID: 7189684
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tolerance to stereotyped behaviour and to decrease in striatal homovanillic acid levels after repeated treatment with apomorphine dipivaloyl ester.
    Worms P; Scatton B
    Eur J Pharmacol; 1977 Oct; 45(4):395-6. PubMed ID: 562764
    [No Abstract]   [Full Text] [Related]  

  • 17. Influence of nootropic drugs on apomorphine-induced stereotyped behaviour in rats.
    Schmidt J
    Biomed Biochim Acta; 1990; 49(1):133-6. PubMed ID: 2360904
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Behavioral effects of apomorphine during development of rats.
    Brus R; Herman ZS; Jamrozik Z
    Acta Physiol Pol; 1977; 28(3):243-6. PubMed ID: 561515
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Apomorphine and piribedil in rats: biochemical and pharmacologic studies.
    Butterworth RF; Poignant JC; Barbeau A
    Adv Neurol; 1975; 9():307-26. PubMed ID: 1170716
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential enhancement of behavioral sensitivity to apomorphine following chronic treatment of rats with (-)-sulpiride and haloperidol.
    Montanaro N; Dall'Olio R; Gandolfi O; Vaccheri A
    Eur J Pharmacol; 1982 Jun; 81(1):1-9. PubMed ID: 6889533
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.